Current challenges for recombinant adeno-associated virus (rAAV) vector–based cancer treatment include the low efficiency and the lack of specificity in vivo. rAAV serotype 3 (rAAV3) vectors have previously been shown to be ineffective in normal mouse tissues following systemic administration. In the present study, we report that rAAV3 vectors can efficiently target and transduce various human liver cancer cells in vivo. Elimination of specific surface-exposed serine and threonine residues on rAAV3 capsids results in further augmentation in the transduction efficiency of these vectors, without any change in the viral tropism and cellular receptor interactions. In addition, we have identified a potential chemotherapy drug, shikonin, as a multifunctional compound to inhibit liver tumor growth as well as to significantly enhance the efficacy of rAAV vector-based gene therapy in vivo. Furthermore, we also document that suppression of tumorigenesis in a human liver cancer xenograft model can be achieved through systemic administration of the optimized rAAV3 vectors carrying a therapeutic gene, and shikonin at a dose that does not lead to liver damage. Our research provides a novel means to achieve not only targeted delivery but also the potential for gene therapy of human liver cancer.
Get full access to this article
View all access options for this article.
References
1.
AslanidiG.V., RiversA.E., OrtizL., et al. (2012). High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine, 30, 3908–3917.
2.
AslanidiG.V., RiversA.E., OrtizL., et al. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: The final threshold?. PLoS One, 8, e59142.
3.
ChenW.Q., ZhengR.S., and ZhangS.W. (2013). Liver cancer incidence and mortality in China, 2009. Chin. J. Cancer, 32, 162–169.
4.
ChengB., LingC., DaiY., et al. (2012). Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther., 19, 375–384.
5.
DaiY., and SiemannD.W. (2010). Bms-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol. Cancer Ther., 9, 1554–1561.
6.
DaiY., BaeK., and SiemannD.W. (2011). Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys., 81, 521–528.
7.
DavidoffA.M., NgC.Y., ZhouJ., et al. (2003). Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood, 102, 480–488.
8.
DongS., and SuS.B. (2014). Advances in mesenchymal stem cells combined with traditional chinese medicine therapy for liver fibrosis. J. Integr. Med., 12, 147–155.
9.
El-SeragH.B. (2011). Hepatocellular carcinoma. N. Engl. J. Med., 365, 1118–1127.
10.
GaoG.P., AlviraM.R., WangL., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA, 99, 11854–11859.
11.
GinnS.L., AlexanderI.E., EdelsteinM.L., et al. (2013). Gene therapy clinical trials worldwide to 2012—an update. J. Gene Med., 15, 65–77.
12.
GlushakovaL.G., LisankieM.J., EruslanovE.B., et al. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab., 98, 289–299.
13.
GongK., and LiW. (2011). Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma. Free Radic. Biol. Med., 51, 2259–2271.
14.
GuY., LinS., LiJ.L., et al. (2012). Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene., 31, 469–479.
15.
HsuS.H., WangB., KotaJ., et al. (2012). Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of mir-122 in liver. J. Clin. Invest., 122, 2871–2883.
16.
JemalA., BrayF., CenterM.M., et al. (2011). Global cancer statistics. CA Cancer J. Clin., 61, 69–90.
17.
KunickC., LauenrothK., LeostM., et al. (2004). 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg. Med. Chem. Lett., 14, 413–416.
18.
LinS., ShenH., LiJ.L., et al. (2013a). Proteomic and functional analyses reveal the role of chromatin reader SFMBT1 in regulating epigenetic silencing and the myogenic gene program. J. Biol. Chem., 288, 6238–6247.
19.
LinS., TianL., ShenH., et al. (2013b). Ddx5 is a positive regulator of oncogenic notch1 signaling in T cell acute lymphoblastic leukemia. Oncogene, 32, 4845–4853.
20.
LingC., LuY., KalsiJ.K., et al. (2010). Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum. Gene Ther., 21, 1741–1747.
21.
LingC., LuY., ChengB., et al. (2011). High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. J. Vis.Exp.
22.
LingC.Q., WangL.N., WangY., et al. (2014a). The roles of traditional Chinese medicine in gene therapy. J. Integr. Med., 12, 67–75.
23.
LingC.Q., YueX.Q., and LingC. (2014b). Three advantages of using traditional Chinese medicine to prevent and treat tumor. J. Integr. Med., 12, 331–335.
24.
LisowskiL., DaneA.P., ChuK., et al. (2014). Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 506, 382–386.
25.
LiuY., JooK.I., and WangP. (2012). Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther., 20, 308–317.
26.
LiuY., FangJ., KimY.J., et al. (2014). Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol. Pharm., 11, 1651–1661.
27.
LlovetJ.M., RicciS., MazzaferroV., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 359, 378–390.
28.
MarkakisE.A., VivesK.P., BoberJ., et al. (2010). Comparative transduction efficiency of AAV vector serotypes 1–6 in the substantia nigra and striatum of the primate brain. Mol. Ther., 18, 588–593.
29.
MarkusicD.M., HerzogR.W., AslanidiG.V., et al. (2010). High-efficiency transduction and correction of murine hemophilia b using aav2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther., 18, 2048–2056.
30.
MelchiorriD., PaniL., GaspariniP., et al. (2013). Regulatory evaluation of Glybera in Europe—two committees, one mission. Nat. Rev. Drug Discov., 12, 719.
31.
MessinaE.L., NienaberJ., DaneshmandM., et al. (2012). Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. Hum. Gene Ther., 23, 1031–1042.
32.
MingozziF., and HighK.A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat. Rev. Genet., 12, 341–355.
33.
MitchellA.M., LiC., and SamulskiR.J. (2013). Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo. J. Virol., 87, 4571–4583.
34.
NathwaniA.C., GrayJ.T., NgC.Y., et al. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 107, 2653–2661.
35.
NathwaniA.C., GrayJ.T., McIntoshJ., et al. (2007). Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human fix in nonhuman primates. Blood, 109, 1414–1421.
36.
PandyaJ., OrtizL., LingC., et al. (2013). Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol. Cell Biol., 92, 116–123.
37.
PengD., QianC., SunY., et al. (2000). Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): In vitro and in vivo effects of genotoxic agents. J. Hepatol., 32, 975–985.
38.
RabinowitzJ.E., BowlesD.E., FaustS.M., et al. (2004). Cross-dressing the virion: The transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol., 78, 4421–4432.
39.
ShaO., NiuJ., NgT.B., et al. (2013). Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: A mini review. Cancer Chemother. Pharmacol., 71, 1387–1393.
40.
SongH.Y., ZhangL., PanJ.L., et al. (2013). Bioactivity of five components of Chinese herbal formula jiangzhi granules against hepatocellular steatosis. J. Integr. Med., 11, 262–268.
41.
SuH., LuR., DingR., and KanY.W. (2000). Adeno-associated viral-mediated gene transfer to hepatoma: Thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals. Mol. Ther., 1, 509–515.
42.
VerslypeC., Van CutsemE., DicatoM., et al. (2009). The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann. Oncol., 20Suppl 7, vii1–vii6.
43.
WangZ., ZhuT., QiaoC., et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol., 23, 321–328.
44.
WangL.N., WangY., LuY., et al. (2014). Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J. Integr. Med., 12, 20–34.
45.
YangH., ZhouP., HuangH., et al. (2009). Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int. J. Cancer, 124, 2450–2459.
46.
YouH., DingW., DangH., et al. (2011). C-met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology, 54, 879–889.
47.
ZhaiX.F., ChenZ., LiB., et al. (2013). Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: A multicenter randomized controlled trial. J. Integr. Med., 11, 90–100.
48.
ZhangF.L., JiaS.Q., ZhengS.P., and DingW. (2010). Celastrol enhances AAV1-mediated gene expression in mice adipose tissues. Gene Ther., 18, 128–134.
49.
ZhangY., WangY., YusufaliA., et al. (2014) Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. J. Integr. Med. (In press).
50.
ZhangY., ZhaoL., LiX., et al. (2014). V8, a newly synthetic flavonoid, induces apoptosis through ROS-mediated ER stress pathway in hepatocellular carcinoma. Arch. Toxicol., 88, 97–107.
51.
ZhongL., LiB., MahC.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA, 105, 7827–7832.
52.
ZhuB., ZhaoL., ZhuL., et al. (2012). Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinβ1 and its related pathway. Toxicol. Appl. Pharmacol., 259, 387–394.
53.
ZincarelliC., SoltysS., RengoG., and RabinowitzJ.E. (2008). Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther., 16, 1073–1080.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
